Sara Adams, MD
Hematology & Oncology · Georgetown, SCNPI 1043397391
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,768 of the $2,324 with a category attached, or 76.1%. 26 manufacturers reported payments, led by Novartis at 38.0% of the total. Reporting peaked in 2019 at $623 and has fallen 51.6% since, to $301 in 2025. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 115 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$883
- Pfizer$230
- E.r. Squibb & Sons, L.L.C.$167
- Merck$162
- Bristol Myers Squibb$137
- Gilead$122
- plus $621 from 20 others
Across 16 payments — averaging $14,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$210K
- Pfizer$19K
- Veru Inc.$6K
- Merck$3K
What the payments were for
- Food & beverage$1,76876%
- Education$121%
- Gifts$54323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $883 |
| Pfizer | 14 | $230 |
| E.r. Squibb & Sons, L.L.C. | 10 | $167 |
| Merck | 10 | $162 |
| Bristol Myers Squibb | 7 | $137 |
| Gilead | 5 | $122 |
| Genentech USA, Inc. | 7 | $114 |
| Amgen | 4 | $75 |
| Johnson & Johnson | 3 | $53 |
| GSK | 2 | $42 |
| Astellas Pharma US Inc | 2 | $42 |
| Eisai Inc. | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Morphosys, US Inc. | 1 | $14 |
| Bayer | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
How this compares
$2,324 in reported general payments places this provider in the 35th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 50 | $744,370 |
| RevlimidLenalidomide | 28 | $613,175 |
| Lenalidomide | 24 | $344,893 |
| FotivdaTivozanib Hcl | 11 | $320,603 |
| PomalystPomalidomide | 15 | $320,285 |
| SprycelDasatinib | 12 | $225,306 |
| KisqaliRibociclib Succinate | 12 | $191,677 |
| Everolimus | 26 | $154,315 |
| Abiraterone Acetate | 24 | $94,226 |
| EliquisApixaban | 76 | $70,472 |
| VenclextaVenetoclax | 14 | $51,808 |
| XareltoRivaroxaban | 17 | $18,588 |
| Letrozole | 318 | $7,891 |
| Exemestane | 44 | $3,541 |
| Imatinib Mesylate | 32 | $3,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $16 | $744,37050 claims |
| Bristol Myers SquibbRevlimid | $137 | $613,17528 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $167 | $545,59027 claims |
| NovartisKisqali | $883 | $191,67712 claims |
| PfizerEliquis | $230 | $70,47276 claims |
| Johnson & JohnsonXarelto | $53 | $18,58817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Georgetown
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
- Sashi NaiduRock Hill$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.